ARCHIVES

FDA To Expand Disclosure For Advisory Committee Members

This article is from The Cancer Letter archive.

Vol. 36 No. 15 | April 23, 2010

Download PDF Visit The Full Archive

Related Articles

Cancer Control Contractors Severally Criticized In Merit Peer Review; Inadequate Reports Cited

May 28, 1976

FDA’s Commitment To Cancer No Different Than Other Diseases, Kessler Tells Advocate

August 14, 1992

Endostatin Enters Phase II Trial For Neuroendocrine Tumors.

December 14, 2001

Radiosensitizer Screen Concept OK’d, Acoustic Microscopy Delayed

March 2, 1990

Murphy Withdraws From SU Position

October 17, 1986

Advisors Ok New RFP For Natural Product Large-Scale Production

March 6, 1992